Acrivon Therapeutics(US:ACRV) Newsfilterยท2024-04-17 00:01Core Insights - Acrivon Therapeutics is hosting a virtual corporate R&D event on April 24, 2024, to present updates on its precision oncology pipeline and engage in an interactive Q&A session [1][2] Company Overview - Acrivon Therapeutics is a clinical stage biopharmaceutical company focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), which identifies patients whose tumors are likely to respond to specific treatments [3] - The AP3 platform measures compound-specific effects on tumor cell protein signaling networks and drug-induced resistance mechanisms, facilitating drug design optimization and the creation of proprietary OncoSignature companion diagnostics [3] Pipeline Developments - The lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [3] - ACR-368 has received Fast Track designation from the FDA for use as monotherapy in patients with platinum-resistant ovarian or endometrial cancer based on OncoSignature-predicted sensitivity [3] - The ACR-368 OncoSignature test, which is not yet approved, has been evaluated in preclinical studies, including two blinded, prospectively-designed studies involving tumor biopsies from previous trials [3] - The FDA has granted Breakthrough Device designation for the ACR-368 OncoSignature assay to identify ovarian cancer patients who may benefit from ACR-368 treatment [3] - Acrivon is also developing ACR-2316, a potent WEE1/PKMYT1 inhibitor, and other preclinical programs leveraging the AP3 platform [3]